BeOne Medicines (NASDAQ:ONC) Stock Price Target Raised at Royal Bank Of Canada

BeOne Medicines (NASDAQ:ONC) had its price target boosted by analysts at Royal Bank Of Canada from $459.00 to $465.00 in a report issued on Friday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada‘s price objective would suggest a potential upside of 13.76% from the stock’s previous close.

A number of other equities analysts also recently weighed in on ONC. Citizens Jmp increased their price target on shares of BeOne Medicines from $405.00 to $463.00 and gave the stock a “market outperform” rating in a research note on Friday. Citigroup restated an “outperform” rating on shares of BeOne Medicines in a report on Thursday, August 6th. Truist Financial reaffirmed a “buy” rating and issued a $448.00 target price (up from $420.00) on shares of BeOne Medicines in a research report on Friday. Nomura lifted their target price on BeOne Medicines from $454.75 to $484.91 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 18th. Sixteen research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $434.79.

BeOne Medicines Price Performance

Shares of NASDAQ:ONC traded up $21.52 on Friday, hitting $408.77. The company had a trading volume of 547,607 shares, compared to its average volume of 318,506. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17. The company has a market cap of $44.88 billion, a PE ratio of 72.00 and a beta of 0.63. BeOne Medicines has a 52-week low of $253.95 and a 52-week high of $409.80. The business has a 50 day moving average of $362.80 and a 200 day moving average of $325.98.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Thursday, November 5th. The company reported $3.64 earnings per share for the quarter, topping analysts’ consensus estimates of $2.34 by $1.30. The company had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.76 billion. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. As a group, equities analysts anticipate that BeOne Medicines will post 8.99 earnings per share for the current fiscal year.

Insider Buying and Selling at BeOne Medicines

In other BeOne Medicines news, insider Xiaodong Wang sold 38,287 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $349.10, for a total value of $13,365,991.70. Following the transaction, the insider directly owned 6,079 shares of the company’s stock, valued at $2,122,178.90. This trade represents a 86.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Xiaobin Wu sold 280 shares of the business’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $380.00, for a total value of $106,400.00. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 376,373 shares of company stock worth $134,848,154. Insiders own 6.19% of the company’s stock.

Hedge Funds Weigh In On BeOne Medicines

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Mather Group LLC. grew its position in BeOne Medicines by 192.0% in the third quarter. Mather Group LLC. now owns 73 shares of the company’s stock valued at $27,000 after acquiring an additional 48 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of BeOne Medicines by 39.5% in the third quarter. GAMMA Investing LLC now owns 120 shares of the company’s stock valued at $44,000 after purchasing an additional 34 shares during the period. Parallel Advisors LLC grew its holdings in BeOne Medicines by 24.0% during the 1st quarter. Parallel Advisors LLC now owns 351 shares of the company’s stock valued at $104,000 after purchasing an additional 68 shares in the last quarter. Provenance Wealth Advisors LLC purchased a new stake in BeOne Medicines during the 3rd quarter worth $106,000. Finally, Knights of Columbus Asset Advisors LLC purchased a new stake in BeOne Medicines during the 3rd quarter worth $106,000. 48.55% of the stock is owned by institutional investors and hedge funds.

More BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Q3 results topped estimates and revenue guidance was raised. BeOne reported adjusted EPS of $3.64 versus the $2.34 consensus and revenue of $1.89 billion versus $1.76 billion expected. The company also raised its 2026 revenue guidance, signaling stronger business expectations. BeOne Q3 earnings and guidance
• Positive Sentiment: FDA granted priority review to a BRUKINSA combination. The review concerns use in first-line mantle cell lymphoma; a label expansion could broaden the drug’s potential market if approved. FDA priority review for BRUKINSA
• Positive Sentiment: Analysts raised their price targets and maintained positive ratings. Barclays lifted its target to $446 with an “overweight” rating; Citizens JMP raised its target to $463 and kept “market outperform”; Wells Fargo raised its target to $435 and retained “overweight.” The revisions reflect improved analyst expectations, though targets are not guarantees of future performance. Barclays rating information Citizens JMP rating information Wells Fargo rating information

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for cancer patients. Formerly known as BeiGene, the company operates an integrated biotechnology platform spanning research, clinical development, regulatory activities and commercial operations.

Its portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used in the treatment of several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy approved in multiple markets for certain cancers.